T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs

Current Opinion in Immunology

Volumn 9, Issue 5, 1997, Pages 648-654

  Smith, Judith A ^a   Bluestone, Jeffrey A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FC RECEPTOR; MONOCLONAL ANTIBODY CD3;

DRUG MECHANISM; GRAFT REJECTION; HELPER CELL; IMMUNOSUPPRESSIVE TREATMENT; REVIEW; T LYMPHOCYTE;

EID: 0030658863     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80044-1     Document Type: Article

References (39)

1. Bretscher P, Cohn M. A theory of self - nonself discrimination. Science. 169:1970;1042-1049.
2. Sperling AI, Bluestone JA. The complexities of T-cell costimulation: CD28 and beyond. Immunol Rev. 153:1996;155-182.
3. Quill H, Schwartz RH. Stimulation of normal inducer T cell clones with antigen presented by purified la molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol. 138:1987;3704-3712.
4. Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol. 144:1990;16-22.
5. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 165:1987;302-319.
6. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of energy in T cell clones. Nature. 356:1992;607-610.
7. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature. 363:1993;156-159.
8. Sloan-Lancaster J, Allen PM. Altered peptide ligand induced partial T cell activation: molecular mechanisms and role in T cell biology. of outstanding interest Annu Rev Immunol. 14:1996;1-27 The authors present a comprehensive review of signaling induced by, and the functional properties of, altered peptide ligands. Models of how partial signals are generated and the role of altered peptide ligands in various aspects of T cell biology are discussed.
9. Madrenas J, Chau LA, Smith J, Bluestone JA, Germain RN. The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. of outstanding interest J Exp Med. 185:1997;219-229 This study examines the role of the CD4 co-receptor in proximal TCR signaling. Limiting the association of CD4 with the TCR complex resulted in a partial agonist pattern of signaling and T cell clonal anergy.
10. Cosimi AB, Burton RC, Colvin B. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation. 32:1981;535-539.
11. Jaffers GJ, Colvin RB, Cosimi AB, Giorgi JV, Goldstein G, Fuller TC, Kurnick JT, Lillehei C, Russell PS. The human immune response to murine OKT3 monoclonal antibody. Transplant Proc. 15:1983;646-648.
12. Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel L, Grau G, Bluestone JA, Bach JF, Chatenoud L. Cytokine related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol. 20:1990;509-515.
13. Charpentier B, Hiesse C, Lantz O, Ferran C, Stephens S, O'Shaugnessy D, Bodmer M, Benoit G, Bach JF, Chatenoud L. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation. 54:1992;997-1002.
14. Kan EAR, Wright SD, Welte K, Wang CY. Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2. Cell Immunol. 98:1986;181-187.
15. Debets JM, Van de Winkel JG, Cueppens IE, Dieteren M, Buurman WA. Cross-linking of both FcγRI and FcγRII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-FcγR interactions: functional activation of FcγRII by treatment with proteases or neuraminidase. J Immunol. 144:1990;1304-1309.
16. Krutmann J, Kirnbauer R, Kock A, Schwarz T, Schopf E, May T, Sehgal PB, Luger TA. Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3 induced T cell activation. J Immunol. 145:1990;1337-1341.
17. Hirsch R, Bluestone JA, DeNenno L, Gress RE. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation. 49:1990;1117-1120.
18. Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA. A non-activating humanized anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 57:1994;1537-1543.
19. Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, Bluestone JA. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol. 155:1995;1544-1555.
20. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immonol. 23:1993;403-411.
21. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. of outstanding interest J Exp Med. 185:1997;1413-1422 This study examines the biological and biochemical consequences of soluble anti-CD3 mAb treatment in naive T cells and T cell clones. Insufficient TCR aggregation by an FcR-nonbinding anti-CD3 mAb induces a signal similar to an altered peptide ligand signal, resulting in clonal, but not naive T cell anergy.
22. Hirsch R, Eckhaus M, Auchincloss H Jr, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol. 140:1988;3766-3772.
23. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell. 76:1994;263-274.
24. Cantrell D. T cell antigen receptor signal transduction pathways. of special interest Annu Rev Immunol. 14:1996;259-274 This is a comprehensive review of T cell receptor signal transduction, especially useful for its discussion of the Ras pathway and the biochemical signaling cascades that link the T cell receptor to the activation of nuclear transcription factors.
25. Su B, Jacinto E, Hibi M, Kallunki T, Kanin M, Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lymphocytes. Cell. 77:1994;727-736.
26. Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM. Partial T cell signaling: altered phospho-zeta and lack of ZAP70 recruitment in APL-induced T cell energy. Cell. 79:1994;913-922.
27. Madrenas J, Wange RL, Wang JL, Isakov N, Samelson LE, Germain RN. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science. 267:1995;515-518.
28. Iwashima M, Irving BA, van Oers NS, Chan AC, Weiss A. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science. 263:1994;1136-1139.
29. 2+ response amplitude and duration. of special interest Nature. 386:1997;855-858 Low calcium levels were sufficient to induce NF-AT translocation, but higher levels were required for NF-κB translocation in B cells. By extension, this study has implications for TCR signals which induce a low calcium flux level.
30. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
31. Hughes C, Wolos JA, Giannini EH, Hirsch R. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J Immunol. 153:1994;3319-3325.
32. 2 fragments resolved diabetes only after the onset of disease, but not when administered beforehand. This study has implications for the required activation state of the target T cells for anti-CD3 antibody treatment and for the mechanism of anti-CD3 induced cytokine deviation.
33. Rooney JW, Hodge MR, McCaffrey PG, Rao A, Glimcher LH. A common factor regulates both Th1- and Th2-specific cytokine gene expression. EMBO J. 13:1994;625-633.
34. Rooney JW, Hoey T, Glimcher LH. Coordinate and cooperative roles for NF-AT and AP-1 in the regulation of the murine IL-4 gene. Immunity. 2:1995;473-483.
35. Healy JI, Dolmetsch RE, Timmerman LA, Cyster JG, Thomas ML, Crabtree GR, Lewis RS, Goodnow CC. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. of special interest Immunity. 6:1997;419-428 This study compares B cell receptor signaling in tolerant and nontolerant hen egg lysozyme specific B cells. In tolerant cells, NF-AT and mitogen activated protein kinase are chronically activated, yet still further inducible. cJun amino terminal kinase (JNK) activation, however, is defective.
36. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 273:1996;104-106.
37. Kundig TM, Shahinian A, Kawai K, Mittrucker HW, Sebzda E, Bachmann MF, Mak TW, Ohashi PS. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity. 5:1996;41-52.
38. Shaw AS, Dustin ML. Making the T cell receptor go the distance: a topological view of T cell activation. Immunity. 6:1997;361-369.
39. Verweij CL, Geerts M, Aarden LA. Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-κB-like response element. J Biol Chem. 266:1991;14179-14182.